As reported a very short time ago in the WSJ Health blog, a federal court granted Teva 180 days of exclusive selling for its generic versions of 2 Merck hypertension medications - Cozaar & Hyzaar. Today's decision won't set the clock to start ticking until Teva receives FDA approval to go-to-market. Thus, a full 180 days of market exclusivity. These drugs target a portion of the $3.6 billion dollar market for hypertension meds. Merck likely will not appeal further but is studying the court's decision.